Aclarion, Inc. Stock

ACON

US6551874091

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 14/08/2026 +03			5-day change	1st Jan Change
2.460 ^USD	+2.50%		+7.42%	-46.52%

08-12	Aclarion Receives Notice Of Allowance For Patent Advancing Accuracy And Adoption Of Nociscan's MR Spectroscopy Scan Process	CI
08-07	Aclarion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Analysts' recommendations: Aclarion, Inc.

06/07/22

Maxim Starts Aclarion at Buy With $3 Price Target

More recommendations

Press Releases: Aclarion, Inc.

08-12	Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process	AQ
08-04	Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology	AQ
07-29	Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026	AQ
07-21	Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice	AQ
07-07	Aclarion Announces Texas Spine Care Center as New CLARITY Site	AQ

More press releases

Managers and Directors: Aclarion, Inc.

Manager	Title	Age	Since
Brent Ness CEO	Chief Executive Officer	59	15/09/2021
Gregory Gould DFI	Director of Finance/CFO	60	02/09/2025
Daniel Keefe PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
William Wesemann BRD	Director/Board Member	69	01/01/2016
David Neal BRD	Director/Board Member	55	01/09/2016
Jeffrey Thramann CHM	Chairman	61	21/04/2022

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACLARION, INC.	+2.50%	+7.42%	-66.38%	-100.00%	7.09M
LONZA GROUP AG	-1.78%	-1.68%	+1.48%	+15.31%	48.42B
REVOLUTION MEDICINES, INC.	+0.85%	-0.70%	+460.88%	+563.55%	43.66B
BEONE MEDICINES AG	-2.40%	-0.23%	+8.13%	+71.41%	39.51B
IQVIA HOLDINGS INC.	-2.01%	-0.85%	+23.85%	+8.73%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+49.65%	32.61B
ASCENDIS PHARMA A/S	+0.38%	-3.23%	-	-	16.32B
MEDPACE HOLDINGS, INC.	-0.59%	-2.06%	+26.35%	+118.09%	16.15B
EUROFINS SCIENTIFIC SE	+0.49%	+0.92%	+4.11%	+23.67%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.43%	+4.70%	+78.74%	+33.31%	13.37B
Average	-0.35%	+1.18%	+61.97%	+87.08%	26.32B
Weighted average by Cap.	-0.91%	+0.59%	+95.82%	+132.94%

See all sector performances

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/08/26	$2.460	+2.50%	35,695
13/08/26	$2.400	+3.45%	106,870
12/08/26	$2.320	+1.75%	66,900
11/08/26	$2.280	-3.39%	34,517
10/08/26	$2.360	+3.06%	43,506

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.460USD

Average target price

7.500USD

Spread / Average Target

+204.88%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	7.09M 6.12M 5.75M 5.23M 9.84M 678M 10M 67.43M 26.36M 340M 26.62M 26.04M 1.13B	P/E 2026 *	-0.55x	P/E 2027 *	-0.45x
Enterprise Value	7.09M 6.12M 5.75M 5.23M 9.84M 678M 10M 67.43M 26.36M 340M 26.62M 26.04M 1.13B	EV / Sales 2026 *	52.5x	EV / Sales 2027 *	27.6x
Free-Float	77.62%	Yield 2026 *	-	Yield 2027 *	-

08-12	Aclarion Receives Notice Of Allowance For Patent Advancing Accuracy And Adoption Of Nociscan's MR Spectroscopy Scan Process	CI
08-07	Aclarion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-04	Aclarion, Inc Announces Nociscan Now Available At Goodman Campbell Brain & Spine At Ascension St. Vincent	CI
07-07	Aclarion Announces Texas Spine Care Center as New CLARITY Site	CI
06-09	Aclarion Launches Market Access Program With PRIA Healthcare	MT
06-08	Echo Lake Capital cancelled the acquisition of Aclarion, Inc..	CI
06-08	Aclarion Rejects Echo Lake Capital's Acquisition Proposal	MT
06-01	Aclarion Demonstrates Potential Clinical Applications Of Nociscan Beyond Surgical Decision Support In New Immune-Biomarker Study	CI
05-28	Aclarion says board to review Echo Lake Capital's acquisition proposal	RE
05-28	Echo Lake Capital proposed to acquire Aclarion, Inc..	CI
05-13	Aclarion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Aclarion, Inc. Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment	CI
05-05	Aclarion announces second commercial agreement with Weill Cornell Medicine	RE

1 day	+2.50%
1 week	+7.42%
Current month	+9.33%
1 month	-7.52%
3 months	-22.15%
6 months	-4.65%
Current year	-46.52%

1 week	2.25	2.47
1 month	1.95	2.65
Current year	1.95	9.36
1 year	1.95	12.03
3 years	1.95	89,552.67
5 years	1.95	586,115.57
10 years	1.95	586,115.57

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/11/26 A	Jeffrey Thramann	Free	Chairman	100,000	4.0613%
6/11/26 A	Gregory Gould	Free	Chief Financial Officer	50,000	2.0307%
11/26/25 A	Brent Ness	Buy	Chief Executive Officer	10	0.0017%

Aclarion, Inc. Stock

Stocks

ACON

US6551874091

Biotechnology & Medical Research

Valuation: Aclarion, Inc.

Chart: Aclarion, Inc.

Latest news : Aclarion, Inc.

Analysts' recommendations: Aclarion, Inc.

Press Releases: Aclarion, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Aclarion, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

	2026 *	2027 *
Net sales	135K 117K 110K 99.65K 187K 12.91M 190K 1.28M 502K 6.46M 507K 496K 21.48M	257K 222K 209K 190K 357K 24.57M 363K 2.44M 956K 12.31M 965K 944K 40.9M
Net income	-10.71M -9.25M -8.69M -7.9M -14.86M -1.02B -15.1M -102M -39.81M -513M -40.2M -39.33M -1.7B	-13.47M -11.63M -10.93M -9.94M -18.69M -1.29B -19M -128M -50.07M -645M -50.56M -49.46M -2.14B
Net Debt	-	-